2-Chloro-4-(Trifluoromethyl)-5-Thiazolecarboxylic Acid Phenylmethyl Ester

In a validated 1600-L glass-lined reactor campaign operated under ISO 10648-2 containment protocols, the phenylmethyl ester functions as a bench-stable, crystalline acyl donor for constructing the sulfonylurea bridge of branched-chain amino acid synthesis (ALS) inhibitors. The downstream active ingredient—typically a trisubstituted aryl sulfonylurea dispatched as a 750 g/kg water-dispersible granule (WG) per FAO Specification 750/WG—relies on a strictly controlled stoichiometric insertion of the thiazole moiety. The molar feed ratio of the ester to 2-amino-4,6-dimethoxypyrimidine is held at 1.02:1.00, with the deliberate 2% excess compensating for mechanical losses during solid-phase dispensing and the formation of a trace O-acylisourea byproduct detectable by HPLC at 0.12–0.25 area-%. Process compliance is anchored to CIPAC Handbook K, MT 172 for purity assignment and FAO/WHO JMPS (2024) decision guidance for relevant impurities: the manufacturing concentrate must exhibit a technical purity ≥ 98.0% on anhydrous basis, with individual unspecified impurities limited to ≤ 0.5% and the residual phenylmethanol content controlled below 800 ppm as verified by headspace GC-FID against an external standard. The synthesis is executed by dissolving the ester in anhydrous tetrahydrofuran (KF ≤ 50 ppm) and charging the solution into a -5 °C pre-cooled mixture of triethylamine and the aminopyrimidine co-reactant over a 45-minute period, maintaining the jacket outlet temperature at -8 °C to -3 °C. After an end-of-addition ripening period of 90 minutes with agitation at 110 rpm in a retreat-curve impeller configuration, the reaction mass is quenched into deionized water at 2 °C and the crude product isolated via pressure filtration through a plate-and-frame filter press fitted with polypropylene cloth (15 μm rating). Recrystallization from a ternary isopropanol/water/heptane system (72:22:6 v/v/v) delivers primary crystal seeds of D90 ≤ 180 µm, which are dried in an agitated vacuum pan dryer at 40 °C and 15 mbar until loss-on-drying ≤ 0.3%. The final herbicide active ingredient, supplied as an off-white crystalline powder, exhibits a characteristic melting endotherm at 172–175 °C by DSC (ASTM E537-20) and is formulated with dispersant systems such as sodium naphthalene sulfonate condensate and polynaphthylmethane sulfonate to yield a granule with complete dispersion in CIPAC Standard Water D within 30 seconds.

What Limits Production Throughput When Converting the Ester to the Free Acid for Quinone-Inside Inhibitor Fungicide Conjugation?

In the manufacture of succinate dehydrogenase inhibitor (SDHI) fungicides aligned with the quinone-inside (Qi) quinone-binding paradigm, the phenylmethyl ester is rarely employed in its intact form; instead, it undergoes chemoselective cleavage to 2-chloro-4-(trifluoromethyl)thiazole-5-carboxylic acid before subsequent activation and amidation with substituted anilines. The critical process constraint that defines the batch cycle time arises during the saponification step, where the ester is treated with an aqueous alkali metal hydroxide in a mixed aqueous-organic solvent matrix. When lithium hydroxide monohydrate (1.08 eq) is dosed into a 40 °C solution of the ester in THF:water (4:1 v/v), the reaction reliably reaches > 99% conversion within 3.5 hours as tracked by UPLC at 254 nm; however, the post-reaction workup sequence introduces a significant vacuum distillation load because the phenylmethanol co-product must be removed to ≤ 0.1 wt% before the acid is forwarded to acyl chloride generation. In campaigns subject to EPA 40 CFR §180.500 tolerances and the associated JMPR Codex Maximum Residue Limit evaluation, the isolated free acid must pass a clarity test—dissolved at 10% w/w in acetonitrile—exhibiting nephelometric turbidity units (NTU) ≤ 5, a metric that directly correlates with incomplete alkali washing of residual benzoic acid analogs formed through trace air oxidation of the benzyl alcohol. The subsequent conversion to the acid chloride illustrates a second bottleneck: using oxalyl chloride (1.15 molar equiv) with catalytic dimethylformamide (0.03 equiv) in toluene at 50 °C, the off-gas composition monitored by FTIR shows CO evolution exceeding 45 mL·min^-1·kg_substrate^-1 before plateauing at 120 minutes. Maintaining a consistent headspace nitrogen sweep of 2.5 reactor volumes·h^-1 and a jacket temperature of 48–52 °C is essential to suppress the formation of the symmetrical anhydride impurity, which otherwise propagates into the final coupled amide at levels above the 0.15% specification threshold dictated by the formulated suspension concentrate (SC) product—typically a 250 g/L active ingredient flowable concentrate requiring a d₉₀ particle size of 2.0 µm after wet bead milling in a horizontal, closed-type mill charged with 0.3–0.5 mm yttria-stabilized zirconia beads. The finished fungicide molecule, once condensed with 2-(1,3-dimethylbutyl)aniline and isolated as an off-white powder with a purity ≥ 97.5% by qNMR (CPMG sequence, D1=30s), is tested for accelerated storage stability at 54 °C for 14 days per CIPAC MT 46.3 to ensure no moisture-induced deamidation reverts the active ingredient below the clinical efficacy threshold.

A further operational boundary appears when the free acid is transferred to the coupling stage without rigorous pre-drying: the moisture content of the toluene-acid mixture must not exceed 150 ppm Karl Fischer, or yield loss to the acyl chloride hydrolysis product—regenerated acid—exceeds 4.0% of theoretical. Plant trials in a 500-L Hastelloy C-22 reactor equipped with a reflux divider and a Dean-Stark trap demonstrated that azeotropic drying at 110 °C for 90 minutes (circulation rate 180 L·h^-1) achieves the required dryness when the ambient dew point in the make-up air is -30 °C or lower; operations during monsoon season in a grade D cleanroom without desiccant rotor dehumidification resulted in 3.4% additional anhydride formation and triggered a batch rejection under the internal alert limit of 0.20% anhydride.

Using the Benzyl Ester as a Latent Carboxylate for Palladium-Catalyzed C–H Activation in Thiazole–Pyridine Chiral Ligands

Within the supply chain for stereoselective catalytic transformations, the phenylmethyl ester enters the synthesis of P,N-ligands built on a 2-chloro-4-(trifluoromethyl)thiazole scaffold, where the carboxylate is temporarily masked to withstand the strongly basic, anhydrous conditions of a Pd(OAc)₂/XPhos-mediated direct arylation. The target ligand auxiliaries—utilized in enantioselective allylic alkylations under NMP at 60 °C—require an intermediate that resists nucleophilic ring-opening at the C2 chlorine position until the final sequential substitution. The ester is charged at 1.00 molar equivalent relative to the 2-bromopyridine coupling partner, along with 3.0 mol-% Pd(OAc)₂, 6.0 mol-% XPhos, and 2.2 equivalents of potassium acetate in N,N-dimethylacetamide (DMAc) containing ≤ 0.01% water. The heterogeneous mixture is sparged with argon for 45 minutes through a sintered metal frit (10–20 µm porosity) before being heated to 105 °C with rigorous stirring at 400 rpm in a baffled 50-L vessel. In-process UPLC monitoring at 215 nm confirms that the benzyl ester survives the entire 16-hour coupling window without detectable transesterification or decarboxylation, an advantage over the corresponding methyl or ethyl ester, which undergo 0.8–2.5% alcoholysis by the liberated acetate under these forcing conditions. The regulatory framework applicable to such pharmaceutical auxiliaries invokes ICH Q3A(R2) for impurity threshold identification and ICH Q3D(R2) for elemental impurities, with palladium residual in the isolated intermediate controlled to ≤ 10 ppm via a charcoal treatment step (Darco G-60, 5% w/w loading, stirred at 70 °C for 2 hours) and subsequent filtration through a 0.5 µm PTFE membrane cartridge. After the cross-coupling, the benzyl group is removed by transfer hydrogenation employing ammonium formate (5.0 equiv) and 10% Pd/C (50% wet) at 25 °C in methanol, a protocol selected specifically to avoid the over-reduction of the thiazole ring observed with H₂-balloon conditions during scale-up. The resultant carboxylic acid is then converted to the oxazoline-phosphine ligand through a phosphine oxide directed installation, ultimately yielding a white crystalline product with a melting range of 158–161 °C and a specific rotation of [α]²⁰_D = -87° (c 1.0, CHCl₃)—properties that are certified in a CoA against Ph. Eur. 2.2.31 and USP 〈781〉. The terminal application lies in kilogram-scale synthesis of a chiral tertiary alcohol intermediate for an oral Factor XIa inhibitor, where the ligand delivers enantiomeric excess values exceeding 98.5% at a substrate-to-catalyst ratio of 2000:1.

In the production of covalent inhibitors targeting the KRAS G12C oncoprotein, the phenylmethyl ester is employed as a protecting group strategy that survives a five-step sequence comprising epoxide opening, TEMPO-mediated oxidation, and a modified Horner–Wadsworth–Emmons olefination, before being unveiled in the penultimate step to furnish a highly polar carboxylic acid payload. The production process, conducted in a multipurpose 100-L jacketed reactor conforming to GMP Part 211 (21 CFR §211.65) equipment cleaning validation protocols, commences with the ester and a chiral epoxide-derived amino alcohol combined in 1:1 stoichiometric ratio under neat conditions at 80 °C to furnish a β-amino alcohol adduct in 92% in-process yield. This secondary amine is next oxidized with a 0.05 M aqueous sodium hypochloride solution buffered at pH 8.5 by sodium bicarbonate and catalyzed by TEMPO (1 mol-%) and potassium bromide (10 mol-%) in a two-phase dichloromethane/water system, where strict temperature control at 0–5 °C is essential to avoid oxidative dechlorination at the thiazole C2 position—a side reaction that if uncorrected produces a mutagenic impurity flagged by an in silico Derek Nexus alert (alert #392, aromatic chloride displacement). The ketone intermediate, after polishing by silica gel plug filtration with ethyl acetate/heptane (30:70 v/v), is subjected to a Horner–Wadsworth–Emmons reaction using trimethyl phosphonoacetate and lithium diisopropylamide (1.05 equiv) in tetrahydrofuran at -20 °C, yielding the α,β-unsaturated ester as a geometric mixture (E/Z = 93:7) that is enriched to > 99% E by thermodynamically controlled isomerization with catalytic iodine (0.05 equiv) in refluxing heptane. The benzyl ester endures this entire telescoped process and is finally cleaved by hydrogenolysis over 5% Pd/BaSO₄ (Rosenmund-type catalyst) under a hydrogen pressure of 1.2 bar in ethyl acetate, a selection mandated by the molecule’s sensitivity to Pd/C-induced defluorination of the trifluoromethyl group under higher pressure. The resultant free acid is precipitated as a crystalline zwitterion by adjusting the mixture to its isoelectric point (approximately pH 4.2), filtered, and dried in a 45 °C vacuum oven to a loss-on-drying below 0.5%. The final drug substance intermediate meets the ICH Q3C(R8) residual solvent limits for ethyl acetate (Class 3, ≤ 5000 ppm) and heptane (Class 3, ≤ 5000 ppm), with the palladium residuum measured by ICP-MS at ≤ 5 ppm consistent with USP 〈232〉 Drug Product limit. The ultimate therapeutic product is a capsule formulation containing 200 mg of the KRAS inhibitor free acid, which in phase 2 clinical supply chains is paired with an acid-reducing co-formulation design to maintain gastric pH-dependent solubility per the biorelevant dissolution method USP Apparatus II at 75 rpm in FaSSGF medium.